Outbreaks of both types of herpes simplex alternate with periods when the virus lies dormant in the nerve cells. The reappearance of blisters may be triggered by such factors as fever, infectious diseases, exposure to sunlight, menstruation, or pregnancy. The blisters usually last from 10 to 14 days. Treatment for recurrent herpes includes elimination of the precipitating conditions, local antibiotic treatment to prevent bacterial infection, and treatment with antiviral drugs such as acyclovir, although some resistant strains (see drug resistance) have developed. There is no cure. The herpes simplex virus is also the cause of a form of viral encephalitis.
See also herpes zoster (shingles).
Herpes simplex virus 1 and 2 (HSV-1 and HSV-2) are two species of the herpes virus family, Herpesviridae, which cause infections in humans. Eight members of herpesviridae infect humans to cause a variety of illnesses including cold sores, chickenpox or varicella, shingles or herpes zoster (VZV), cytomegalovirus (CMV), and various cancers, and can cause brain inflammation (encephalitis). All viruses in the herpes family produce life-long infections.
They are also called Human Herpes Virus 1 and 2 (HHV-1 and HHV-2) and are neurotropic and neuroinvasive viruses; they enter and hide in the human nervous system, accounting for their durability in the human body. HSV-1 is commonly associated with herpes outbreaks of the face known as cold sores or fever blisters, whereas HSV-2 is more often associated with genital herpes.
An infection by a herpes simplex virus is marked by watery blisters in the skin or mucous membranes of the mouth, lips or genitals. Lesions heal with a scab characteristic of herpetic disease. However, the infection is persistent and symptoms may recur periodically as outbreaks of sores near the site of original infection. After the initial, or primary, infection, HSV becomes latent in the cell bodies of nerves in the area. Some infected people experience sporadic episodes of viral reactivation, followed by transportation of the virus via the nerve's axon to the skin, where virus replication and shedding occurs.
Herpes is contagious if the carrier is producing and shedding the virus. This is especially likely during an outbreak but possible at other times. There is no cure yet, but there are treatments which reduce the likelihood of viral shedding.
HSV is transmitted during close contact with an infected person who is shedding virus from the skin, in saliva or in secretions from the genitals. This horizontal transmission of the virus is more likely to occur when sores are present, although viral shedding, and therefore transmission, does occur in the absence of visible sores. In addition, vertical transmission of HSV may occur between mother and child during childbirth, which can be fatal to the infant. The immature immune system of the child is unable to defend against the virus and even if treated, the infection can result in inflammation of the brain (encephalitis) that may cause brain damage. Transmission occurs when the infant passes through the birth canal, but the risk of infection is reduced if there are no symptoms or exposed blisters during delivery. The first outbreak after exposure to HSV is commonly more severe than future outbreaks, as the body has not had a chance to produce antibodies; this first outbreak carries a low (~1%) risk of developing aseptic meningitis.
The genomes of HSV-1 and HSV-2 are complex, and contain two unique regions called the long unique region (UL) and the short unique region (US). Of the 74 known ORFs, UL contains 56 viral genes, whereas US contains only 12. Transcription of HSV genes is catalyzed by RNA polymerase II of the infected host. Immediate early genes, which encode proteins that regulate the expression of early and late viral genes, are the first to be expressed following infection. Early gene expression follows, to allow the synthesis of enzymes involved in DNA replication and the production of certain envelope glycoproteins. Expression of late genes occurs last; this group of genes predominantly encode proteins that form the virion particle.
Five proteins from (UL) form the viral capsid; UL6, UL18, UL35, UL38 and the major capsid protein UL19.
|The open reading frames (ORFs) of HSV-1|
|UL1||Glycoprotein L||Surface and membrane||UL38||UL38; VP19C||Capsid assembly and DNA maturation|
|UL2||UL2||Uracil-DNA glycosylase||UL39||UL39||Ribonucleotide reductase (Large subunit)|
|UL3||UL3||unknown||UL40||UL40||Ribonucleotide reductase (Small subunit)|
|UL4||UL4||unknown||UL41||UL41; VHS||Tegument protein; Virion host shutoff|
|UL5||UL5||DNA replication||UL42||UL42||DNA polymerase processivity factor|
|UL6||UL6||Processing and packaging DNA||UL43||UL43||Membrane protein|
|UL7||UL7||Virion maturation||UL44||Glycoprotein C||Surface and membrane|
|UL8||UL8||DNA helicase/primase complex-associated protein||UL45||UL45||Membrane protein; C-type lectin|
|UL9||UL9||Replication origin-binding protein||UL46||VP11/12||Tegument proteins|
|UL10||Glycoprotein M||Surface and membrane||UL47||UL47; VP13/14||Tegument protein|
|UL11||UL11||virion exit and secondary envelopment||UL48||VP16 (Alpha-TIF)||Virion maturation; activate IEGs by interacting with the cellular transcription factors Oct-1 and HCF. Binds to the sequence 5'TAATGARAT3'.|
|UL12||UL12||Alkaline exonuclease||UL49||UL49A||Envelope protein|
|UL13||UL13||Serine-threonine protein kinase||UL50||UL50||dUTP diphosphatase|
|UL14||UL14||Tegument protein||UL51||UL51||Tegument protein|
|UL15||Terminase||Processing and packaging of DNA||UL52||UL52||DNA helicase/primase complex protein|
|UL16||UL16||Tegument protein||UL53||Glycoprotein K||Surface and membrane|
|UL17||UL17||Processing and packaging DNA||UL54||IE63; ICP27||Transcriptional regulation|
|UL19||VP5||Major capsid protein||UL56||UL56||Unknown|
|UL20||UL20||Membrane protein||US1||ICP22; IE68||Viral replication|
|UL22||Glycoprotein H||Surface and membrane||US3||US3||Serine/threonine-protein kinase|
|UL23||Thymidine kinase||Peripheral to DNA replication||US4||Glycoprotein G||Surface and membrane|
|UL24||UL24||unknown||US5||Glycoprotein J||Surface and membrane|
|UL25||UL25||Processing and packaging DNA||US6||Glycoprotein D||Surface and membrane|
|UL26||P40; VP24; VP22A||Capsid protein||US7||Glycoprotein I||Surface and membrane|
|UL27||Glycoprotein B||Surface and membrane||US8||Glycoprotein E||Surface and membrane|
|UL28||ICP18.5||Processing and packaging DNA||US9||US9||Tegument protein|
|UL29||UL29||Major DNA-binding protein||US10||US10||Capsid/Tegument protein|
|UL30||DNA polymerase||DNA replication||US11||US11; Vmw21||Binds DNA and RNA|
|UL31||UL31||Nuclear matrix protein||US12||ICP47; IE12||Inhibits MHC class I pathway by preventing binding of antigen to TAP|
|UL32||UL32||Envelope glycoprotein||RS1||ICP4; IE175||Activates gene transcription|
|UL33||UL33||Processing and packaging DNA||ICP0||ICP0; IE110; α0||E3 ubiquitin ligase that activates viral gene transcription and counteracts the interferon response|
|UL34||UL34||Inner nuclear membrane protein||LRP1||LRP1||Latency-related protein|
|UL35||VP26||Capsid protein||LRP2||LRP2||Latency-related protein|
|UL36||UL36||Large tegument protein||RL1||RL1; ICP34.5||Neurovirulence factor. Antagonizes PKR by de-phosphorylating eIF4a.|
|UL37||UL37||Capsid assembly||LAT||none||Latency-associated transcript|
Entry of HSV into the host cell involves interactions of several glycoproteins on the surface of the enveloped virus, with receptors on the surface of the host cell. The envelope covering the virus particle, when bound to specific receptors on the cell surface, will fuse with the host cell membrane and create an opening, or pore, through which the virus enters the host cell.
The sequential stages of HSV entry are analogous to those of other viruses. At first, complementary receptors on the virus and the cell surface bring the viral and cell membranes into proximity. In an intermediate state, the two membranes begin to merge, forming a hemifusion state. Finally, a stable entry pore is formed through which the viral envelope contents are introduced to the host cell. In the case of a herpes virus, initial interactions occur when a viral envelope glycoprotein called glycoprotein C (gC) binds to a cell surface particle called heparan sulfate. A second glycoprotein, glycoprotein D (gD), binds specifically to a receptor called the herpesvirus entry mediator receptor (HVEM) and provides a strong, fixed attachment to the host cell. These interactions bring the membrane surfaces into mutual proximity and allow for other glycoproteins embedded in the viral envelope to interact with other cell surface molecules. Once bound to the HVEM, gD changes its conformation and interacts with viral glycoproteins H (gH) and L (gL), which form a complex. The interaction of these membrane proteins results in the hemifusion state. Afterward, gB interaction with the gH/gL complex creates an entry pore for the viral capsid. Glycoprotein B interacts with glycosaminoglycans on the surface of the host cell.
After the viral capsid enters the cellular cytoplasm, it is transported to the cell nucleus. Once attached to the nucleus at a nuclear entry pore, the capsid ejects its DNA contents via the capsid portal. The capsid portal is formed by twelve copies of portal protein, UL6, arranged as a ring; the proteins contain a leucine zipper sequence of amino acids which allow them to adhere to each other. Each icosahedral capsid contains a single portal, located in one vertex. The DNA exits the capsid in a single linear segment.
The early proteins transcribed are used in the regulation of genetic replication of the virus. On entering the cell, an α-TIF protein joins the viral particle and aids in immediate-early transcription. The virion host shutoff protein (VHS or UL41) is very important to viral replication. This enzyme shuts off protein synthesis in the host, degrades host mRNA, helps in viral replication, and regulates gene expression of viral proteins. The viral genome immediately travels to the nucleus but the VHS protein remains in the cytoplasm.
The late proteins are used in to form the capsid and the receptors on the surface of the virus. Packaging of the viral particles - including the genome, core and the capsid - occurs in the nucleus of the cell. Here, concatemers of the viral genome are separated by cleavage and are placed into pre-formed capsids. HSV-1 undergoes a process of primary and secondary envelopment. The primary envelope is acquired by budding into the inner nuclear membrane of the cell. This then fuses with the outer nuclear membrane releasing a naked capsid into the cytoplasm. The virus acquires its final envelope by budding into cytoplasmic vesicles.
A protein found in neurons may bind to herpes virus DNA and regulate latency. Herpes virus DNA contains a gene for a protein called ICP4, which an important transactivator of genes associated with lytic infection in HSV-1. Elements surrounding the gene for ICP4 bind a protein known as the human neuronal protein Neuronal Restrictive Silencing Factor (NRSF) or human Repressor Element Silencing Transcription Factor (REST). When bound to the viral DNA elements, histone deacytalization occurs atop the ICP4 gene sequence to prevent initiation of transription from this gene, thereby preventing transcription of other viral genes involved in the lytic cycle. Another HSV protein reverses the inhibition of ICP4 protein synthesis. ICP0 dissociates NRSF from the ICP4 gene and thus prevents silencing of the viral DNA.
The virus can be reactivated by other illnesses such as cold and influenza, eczema, emotional and physical stress, exposure to bright sunlight, gastric upset, fatigue or injury, and menstruation.